Beijing Balance Medical Technology Co., Ltd. announced that the company's self-developed first all-comer interventional pulmonary valve and delivery system has been approved by the Medical Devices Technical Review Center of the National Medical Products Administration, entering the special review procedure for innovative medical instruments. The acceptance number is CQTS2400369, and the product management category is Class III. This product is specifically intended for patients requiring catheter-based artificial biological pulmonary valve replacement following surgical repair and reconstruction of the outflow tract of the right ventricle due to complex congenital heart disease.
佰仁医疗：自主研发的介入肺动脉瓣及输送系统进入创新医疗器械特别审查程序
Beijing Balance Medical Technology Co., Ltd.: The self-developed interventional pulmonary valve and delivery system has entered the special review procedure for innovative medical instruments.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha
【November 2024】Has disney's predicament turned around? Pay attention to these 3 performance signals.
As the entertainment kingdom for nearly a century, Disney's status in Hollywood has gained prominence. Over 60 years of listing on the U.S. stock market, Disney